LLY - Stock held $720 support next level at $760LLY - Stock back to bouncing off $720 support level on the weekly time frame. Needs to break and hold $760 resistance level for a move towards $800 . Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial. calls above $760 look good for a move towards $800
411.10 THB
364.17 B THB
1.55 T THB
849.67 M
About Eli Lilly and Company
Sector
Industry
CEO
Payong Srivanich
Website
Headquarters
Bangkok
Founded
1966
ISIN
TH0150123907
FIGI
BBG01SRM8FN2
Krung Thai Bank Public Co., Ltd. engages in the provision of commercial banking services. It operates through the following business segments: Retail Banking, Corporate Banking, Treasury and Investment, and Support and Others. The Retail Banking segment develops financial products and services. The Corporate Banking segment provides credit facilities and financial services to corporate clients. The Treasury and Investment segment controls the company's financial structure. The Support and Others segment includes middle offices, back offices, subsidiaries, and associated companies. The company was founded on March 14, 1966 and is headquartered in Bangkok, Thailand.
Eli Lilly Stock Down 10.9% Over Past YearTop or Consolidation? Here's My Take...
It's not crystal clear — I can see the case for both. But after years of chart-watching, this doesn't quite look like a top to me:
• Lacks symmetry
• Had chances to break down, but no real follow-through
🧭 Where are we headed?
I think pressure remains, and we
Eli Lillly $LLYNYSE:LLY – Long Setup Ahead of June FOMC
Eli Lilly remains fundamentally strong, with robust growth in revenue (+45% YoY), driven by weight-loss and diabetes drugs like Mounjaro and Zepbound. Despite this, the stock saw a recent pullback after a lowered FY25 profit outlook.
Technical View:
LLY is
Can Lilly Redefine Weight Loss Market Leadership?Eli Lilly is rapidly emerging as a dominant force in the burgeoning weight loss drug market, presenting a significant challenge to incumbent leader Novo Nordisk. Lilly has demonstrated remarkable commercial success despite its key therapy, Zepbound (tirzepatide), entering the market well after Novo
Eli Lilly (LLY) Shares Fall Over 15% in MayEli Lilly (LLY) Shares Fall Over 15% in May
The share price of Eli Lilly and Company (LLY), the world’s largest pharmaceutical company, has seen a sharp shift in market sentiment:
→ From its April low to high, LLY shares rose by over 30%;
→ However, since the start of May, the LLY stock price has
LLY bullish reversal confirmed.. BUY BUY BUYLLY bully reversal is absolutely confirmed
We have the following confirmations
1) closed above 20 day EMA
2) closed above 50 day EMA
3) closed above 200 day EMA
4) RSI above 60
wait till another candle closes above 200 day EMA
Buy at 866
Stop loss @ 790
TP @ 964
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
US532457AM0
ELI LILLY 2025Yield to maturity
16.90%
Maturity date
Jun 1, 2025
LLYC
ELI LILLY 15/25Yield to maturity
11.70%
Maturity date
Jun 1, 2025
XS238628644
ELI LILLY 21/43Yield to maturity
7.97%
Maturity date
Sep 14, 2043
US532457BY3
ELI LILLY 20/50Yield to maturity
7.68%
Maturity date
May 15, 2050
US532457BZ0
ELI LILLY 20/60Yield to maturity
7.57%
Maturity date
Sep 15, 2060
US532457BU1
ELI LILLY 19/59Yield to maturity
6.56%
Maturity date
Mar 15, 2059
US532457BT4
ELI LILLY 19/49Yield to maturity
6.54%
Maturity date
Mar 15, 2049
LLY4217068
Eli Lilly and Company 3.7% 01-MAR-2045Yield to maturity
6.39%
Maturity date
Mar 1, 2045
US532457BS6
ELI LILLY 19/39Yield to maturity
6.38%
Maturity date
Mar 15, 2039
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047Yield to maturity
6.31%
Maturity date
May 15, 2047
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
6.24%
Maturity date
Feb 27, 2063
See all LLY80 bonds
Curated watchlists where LLY80 is featured.